Riskpilot← Back to searchSign inGet full accessAfyx Therapeutics A/S
A/SActiveCVR 38793594Slotsmarken 11Manufacture of pharmaceutical preparations · NACE 2120Est. 201712 employeeswww.afyxtx.com
Revenue 2024
DKK 23,5M
+266% vs 2023
EBITDA margin
-1.0%
+93% vs 2023
Equity ratio
62.5%
Financial strength
Net profit 2024
DKK -3,8M
-69% vs 2023
| Revenue | DKK 23,5M | +266% |
| EBITDA | DKK -227K | +93% |
| Net profit | DKK -3,8M | -69% |
| Total assets | DKK 15,5M | -2% |
| Equity | DKK 9,7M | +104% |
| Employees | 12 | — |
Legal name
Afyx Therapeutics A/S
CVR number
38793594
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
12. juli 2017
Share capital
DKK 20.008.777
Employees
12 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af selskabets administrerende direktør og et medlem af bestyrelsen i forening.
Company purpose
Selskabets formål er at foretage salg og udvikling af lægemidler, behandlinger og medicinsk udstyr til brug globalt, samt andre aktiviteter der står i forbindelse hermed.
Address
Slotsmarken 11
Phone
+4571747174
Email
cm@inphena.com
Website
www.afyxtx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -586 | 1.509 | -3.222 | 6.405 | 23.468 |
| Staff expenses | -721 | -1.972 | -2.388 | -4.174 | -13.709 |
| EBITDA | -1.307 | -463 | -5.610 | -3.085 | -227 |
| Depreciation & amort. | -318 | -562 | -1.010 | -1.271 | -7 |
| EBIT | -1.625 | -1.025 | -6.620 | -4.356 | -234 |
| Net financials | -65 | -161 | -99 | -290 | -1.342 |
| Profit before tax | -1.690 | -1.186 | -6.719 | -4.646 | -1.576 |
| Tax | -183 | -371 | 555 | -2.393 | 2.235 |
| Net profit | -1.507 | -814 | -7.274 | -2.253 | -3.811 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6.095 | 9.776 | 13.407 | 15.826 | 15.463 |
| Equity | 4.696 | 6.243 | -1.031 | 4.741 | 9.660 |
| Long-term debt | 1.059 | 0 | 0 | 0 | 0 |
| Short-term debt | 340 | 3.533 | 14.438 | 6.981 | 5.803 |
| Total debt | 1.399 | 3.533 | 14.438 | 6.981 | 5.803 |
EBITDA margin
-1.0%
This company
15.8%
Market median
-106% vs market
20202024
Equity ratio
62.5%
This company
38.2%
Market median
+64% vs market
20202024
Return on equity
-39.4%
This company
18.4%
Market median
-314% vs market
20202024
Net profit margin
-16.2%
This company
8.1%
Market median
-300% vs market
20202024
Asset turnover
1.52×
This company
1.12×
Market median
+36% vs market
20202024
Debt / equity
0.60×
This company
0.62×
Market median
+3% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CJ Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2024 | |
| Individual | 5–9.99% | 5–9.99% | 2021 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Individual | 5–9.99% | 5–9.99% | 2018 | |
| Individual | 25–33.32% | 25–33.32% | 2021 | |
| Individual | 5–9.99% | 5–9.99% | 2017 | |
| Company | 5–9.99% | 5–9.99% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Afyx Capital ApS
Afyx Therapeutics A/S Board members of Afyx Therapeutics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claus Juan Møller-San Pedro | Chief Executive Officer | 0 companies |
| Ole Baadsgaard | Chairman | 0 companies |
| Pia Leah Møller-San Pedro | Board of Directors | 0 companies |
| Søren Mohrsen Kjær | Board of Directors | 0 companies |